Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
暂无分享,去创建一个
F. Martinez | R. Brook | B. Celli | J. Vestbo | J. Yates | D. Newby | P. Calverley | C. Crim | Julie A. Anderson | S. Kilbride | A. P. Holmes | J. Anderson
[1] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[2] J. Curtis,et al. Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function , 2015, The Journal of Immunology.
[3] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.
[4] P. Scanlon,et al. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? , 2015, American journal of respiratory and critical care medicine.
[5] Kayleigh Kew,et al. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[6] Sanjay Sethi,et al. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. , 2013, The Journal of infectious diseases.
[7] F. Martinez,et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.
[8] Theresa M. Ames,et al. Glucocorticoids Relieve Collectin-Driven Suppression of Apoptotic Cell Uptake in Murine Alveolar Macrophages through Downregulation of SIRPα , 2012, The Journal of Immunology.
[9] A. Sharafkhaneh,et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.
[10] T. Seemungal,et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.
[11] P. Jones,et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.
[12] A. Anzueto,et al. Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.
[13] M. Peters-Golden,et al. Eff erocytosis impairs pulmonary macrophage and lung antibacterial function via PGE 2 / EP 2 signaling , 2009 .
[14] T. Murphy,et al. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[15] W. Janssen,et al. Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. , 2008, American journal of respiratory and critical care medicine.
[16] A. Anzueto,et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.
[17] A. Anzueto,et al. Effect of fluticasone propionate/salmeterol (250/50 g) or salmeterol (50 g) on COPD exacerbations , 2008 .
[18] N. McElvaney,et al. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke , 2007, Respiratory research.
[19] Robert A Wise,et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.
[20] T. Goldmann,et al. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients , 2005, Respiratory research.
[21] W. Thompson,et al. The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] S. Rooney,et al. Pulmonary surfactant secretion in briefly cultured mouse type II cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[23] J. Whitsett,et al. Pulmonary collectins and innate host defense of the lung. , 2001, Microbes and infection.
[24] D. Voelker,et al. KGF increases SP-A and SP-D mRNA levels and secretion in cultured rat alveolar type II cells. , 1998, American journal of respiratory cell and molecular biology.
[25] J. Vestbo,et al. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. , 1995, The European respiratory journal.
[26] DifcoTM HycheckTM,et al. The package insert. , 1969, JAMA.